AVTE, NGM

Aerovate Therapeutics, Inc. (AVTE)

Price (as of October 26)

21USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

ANTX

AN2 Therapeutics, Inc.

-0.16

GMTX

Gemini Therapeutics, Inc.

-0.14

ANPC

AnPac Bio-Medical Science Co., Ltd.

-0.13

ALRN

Aileron Therapeutics, Inc.

-0.13

GNPX

Genprex, Inc.

-0.12

APRE

Aprea Therapeutics, Inc.

-0.12

CINC

CinCor Pharma, Inc.

-0.12

GRPH

Graphite Bio, Inc.

-0.11

AMTI

Applied Molecular Transport Inc.

-0.11

CVM

CEL-SCI Corporation

-0.11

Show more

Highest within Industry

Symbol Correlation

BCAB

BioAtla, Inc.

0.28

AVXL

Anavex Life Sciences Corp.

0.24

BEAM

Beam Therapeutics Inc.

0.21

AVEO

AVEO Pharmaceuticals, Inc.

0.21

AVIR

Atea Pharmaceuticals, Inc.

0.19

APTO

Aptose Biosciences Inc.

0.19

BCDA

BioCardia, Inc.

0.16

ATAI

Atai Life Sciences N.V.

0.15

AKBA

Akebia Therapeutics, Inc.

0.14

IMRX

Immuneering Corporation

0.13

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.